Last reviewed · How we verify
Endostar
At a glance
| Generic name | Endostar |
|---|---|
| Also known as | Recombinant Human Endostatin Injection, rh-Endostatin, recombinant human endostatin injection, Human recombinant vascular endothelial inhibitor, recombinant human endostatin |
| Sponsor | Peng Yuan |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions (PHASE3)
- Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma (PHASE1, PHASE2)
- Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (PHASE2)
- Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (PHASE2)
- Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (PHASE2)
- Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial (PHASE2)
- Local Injection and Systemic Therapy in the Treatment of NSCLC. (PHASE2)
- Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endostar CI brief — competitive landscape report
- Endostar updates RSS · CI watch RSS
- Peng Yuan portfolio CI